Search Within

Michael Andrew Postow

  1. "GSK Faculty"
Formats
  1. Journal Article (100)
  2. Meeting Abstract (74)
  3. Research Letter (2)
  4. Book Section (1)
  5. Review (1)
Groups
  1. Department of Medicine (178)
  2. GSK Faculty (178)
  3. Melanoma Disease Management Team (178)
  4. Melanoma and Immunotherapeutics Service (178)
  5. Solid Tumor Oncology Division (178)
  6. Hematologic Malignancies, Division of (79)

More Groups

People
  1. Jedd Wolchok (158)
  2. Margaret Callahan (82)
  3. Paul Chapman (51)
  4. Alexander Shoushtari (49)
  5. Katherine Panageas (46)
  6. Parisa Momtaz (30)

More People

Years
  1. 2025 (3)
  2. 2024 (3)
  3. 2023 (6)
  4. 2022 (7)
  5. 2021 (12)
  6. 2020 (13)

More Years

Publications
  1. Journal of Clinical Oncology (50)
  2. Journal for ImmunoTherapy of Cancer (18)
  3. Clinical Cancer Research (9)
  4. International Journal of Radiation Oncology, Biology, Physics (9)
  5. New England Journal of Medicine (7)
  6. European Journal of Cancer (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (51)
  2. Biomed Central Ltd (18)
  3. Elsevier Inc. (18)
  4. American Association for Cancer Research (14)
  5. Oxford University Press (12)
  6. Wiley Blackwell (12)

More Publishers

Results (178)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors
    Meeting Abstract

    Friedman, C. F.; Wolchok, J. D.; Postow, M. A.; Shoushtari, A. N.; Callahan, M. K.; Momtaz, P.; Chapman, P. B.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Monotherapy dose escalation clinical and translational data from first-in-human study in advanced solid tumors of IPI-549, an oral, selective, PI3K-gamma inhibitor targeting tumor macrophages
    Meeting Abstract

    Hong, D.; Tolcher, A.; Sullivan, R.; Shapiro, G.; Chmielowski, B.; Ribas, A.; Brail, L.; Pearlberg, J.; Mahabhashyam, S.; Lee, L.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Phase 1/1b, first-in-human study of the PI3K-gamma inhibitor IPI-549 as monotherapy and combined with nivolumab in patients with advanced solid tumors
    Meeting Abstract

    Ribas, A.; Hong, D.; Tolcher, A.; Sullivan, R.; Shapiro, G.; Chmielowski, B.; Brail, L.; Lee, L.; Mahabhashyam, S.; Ullmann, C. D.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Pooled 3-year overall survival data from phase II and phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma
    Meeting Abstract

    Postow, M.; Larkin, J.; Wolchok, J.; Chiarion-Sileni, V.; Hodi, F. S.; Rutkowsk, P.; Grob, J. J.; Grossmann, K.; Schadendorf, D.; Chesney, J.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Clinical and morphologic characteristics of MEK inhibitor - Associated retinopathy: Differences from central serous chorioretinopathy
    Journal Article

    Francis, J. H.; Habib, L. A.; Abramson, D. H.; Yannuzzi, L. A.; Heinemann, M.; Gounder, M. M.; Grisham, R. N.; Postow, M. A.; Shoushtari, A. N.; Chi, P.; more...
    Ophthalmology (2017)

    Fulltext@MSK | Save
  • Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
    Journal Article

    Momtaz, P.; Harding, J. J.; Ariyan, C.; Coit, D. G.; Merghoub, T.; Gasmi, B.; You, D.; Viale, A.; Panageas, K. S.; Samoila, A.; more...
    Oncotarget (2017)

    Fulltext@MSK | Save
  • Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials
    Journal Article

    Schadendorf, D.; Wolchok, J. D.; Hodi, F. S.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Chesney, J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Long-term survival after stereotactic and hypofractionated radiation therapy in patients with metastatic melanoma brain metastases
    Meeting Abstract

    Casey, D. L.; Yamada, Y.; Chan, T. A.; Yang, T. J.; Wolchok, J. D.; Postow, M. A.; Brennan, C. W.; Tabar, V. S.; Gutin, P. H.; Beal, K.
    International Journal of Radiation Oncology, Biology, Physics (2017)

    Fulltext@MSK | Save
  • Improved survival and intracranial control associated with radiation necrosis after ipilimumab and stereotactic radiosurgery for melanoma brain metastases
    Meeting Abstract

    Wild, A.; Kiess, A. P.; Yang, T. J.; Weg, E. S.; Kohutek, Z. A.; Wolchok, J. D.; Postow, M. A.; Tabar, V. S.; Brennan, C. W.; Chan, T. A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2017)

    Fulltext@MSK | Save